These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 10342996)
1. The changing environment in health care. Beers DO Food Drug Law J; 1995; 50(2):293-4. PubMed ID: 10342996 [No Abstract] [Full Text] [Related]
2. Regulating manufacturer-affiliated communication in the information age. Schulman KA; Abernethy DR; Rathore SS; Woosley RL Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664 [No Abstract] [Full Text] [Related]
3. Competition and antitrust enforcement in the changing pharmaceutical marketplace. Whitener MD Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998 [No Abstract] [Full Text] [Related]
4. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004. Seay M Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309 [No Abstract] [Full Text] [Related]
5. A conversation with Debra Dullinger, PharmD. Dullinger D Med Interface; 1994 Oct; 7(10):71-4. PubMed ID: 10137568 [TBL] [Abstract][Full Text] [Related]
6. Adverse selection in private, stand-alone drug plans and techniques to reduce it. Boccuti C; Moon M Policy Brief Commonw Fund; 2003 Oct; (681):1-9. PubMed ID: 14562798 [No Abstract] [Full Text] [Related]
7. A whole new world?: pharmaceutical responses to the managed care revolution. Balto DA Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712 [No Abstract] [Full Text] [Related]
8. Medicare program: Medicare Advantage and Prescription Drug Benefit programs: final marketing provisions. Final rule. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2008 Sep; 73(182):54207-23. PubMed ID: 18985950 [TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses. Mahinka SP; Sanzo KM Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000 [No Abstract] [Full Text] [Related]
10. Targeting formulary pull-through strategies: the role of pharmaceutical manufacturers. Navarro RP Manag Care Interface; 1999 May; 12(5):84-6. PubMed ID: 10537482 [No Abstract] [Full Text] [Related]
11. States combat drug costs. Consum Rep; 2002 Dec; 67(12):8-9. PubMed ID: 12448442 [No Abstract] [Full Text] [Related]
12. Unraveling the ramifications of recent pharmaceutical industry acquisitions by looking at the past, present and future of PBMs (pharmacy benefit management firms). Herzfeld JD Empl Benefits J; 1995 Mar; 20(1):20-3, 30. PubMed ID: 10142515 [No Abstract] [Full Text] [Related]
13. Is it risky to ride with a drug company? McCarthy R Bus Health; 1996 Jan; 14(1):30-4, 36. PubMed ID: 10156381 [No Abstract] [Full Text] [Related]
14. Chronic conditions and disabilities: trends and issues for private drug plans. Boccuti C; Moon M; Dowling K Policy Brief Commonw Fund; 2003 Oct; (680):1-10. PubMed ID: 14562797 [No Abstract] [Full Text] [Related]
15. A sustainable future?: the role of premium subsidies in Medicare prescription drug plans. Demchak C Find Brief; 2007 Jan; 10(2):1-6. PubMed ID: 17302011 [No Abstract] [Full Text] [Related]
16. Caught in between: prescription drug coverage of Medicare beneficiaries near poverty. Shea DG; Stuart BC; Briesacher B Issue Brief (Commonw Fund); 2003 Aug; (669):1-8. PubMed ID: 12926411 [No Abstract] [Full Text] [Related]
17. Medicare program; Medicare prescription drug discount card; revision of marketing rules for endorsed drug card sponsors. Final rule. Centers for Medicare & Medicaid Services, HHS Fed Regist; 2005 Sep; 70(169):52019-23. PubMed ID: 16138430 [TBL] [Abstract][Full Text] [Related]
18. Medicaid and the unconstitutional dimensions of prior authorization. Ranjan JN Mich Law Rev; 2002 Nov; 101(2):602-47. PubMed ID: 12632592 [No Abstract] [Full Text] [Related]
19. Too big? Caremark, AdvancePCS getting close look from feds. Becker C Mod Healthc; 2004 Jan; 34(2):14, 16. PubMed ID: 14959629 [No Abstract] [Full Text] [Related]